Zika virus is transmitted to people primarily through the bite of an infected Aedes species mosquito, the mosquitoes that alos spread dengue and chikungunya viruses.

Phase I Human Trial of Zika Vaccine Approved

"We are proud to have attained the approval to initiate the first Zika vaccine study in human volunteers," said Dr. J. Joseph Kim, Inovio Pharmaceuticals, Inc.'s president and CEO. "We plan to dose our first subjects in the next weeks and expect to report phase I interim results later this year."

Inovio Pharmaceuticals, Inc. (Plymouth Meeting, Pa., and San Diego, Calif.) and GeneOne Life Science, Inc. (Seoul, South Korea) have received approval to initiate a phase I human trial to evaluate Inovio's Zika DNA vaccine to prevent infection from the virus, the companies announced June 20. In preclinical testing, the synthetic vaccine "induced robust antibody and T cell responses in small and large animal models, demonstrating the product's potential to prevent infection from this harmful pathogen in humans," they reported.

Their phase I, open-label, dose-ranging study with 40 healthy subjects will evaluate vaccine's safety, tolerability, and immunogenicity.

"We are proud to have attained the approval to initiate the first Zika vaccine study in human volunteers. As of May 2016, 58 countries and territories reported continuing mosquito-borne transmission of the Zika virus; the incidences of viral infection and medical conditions caused by the virus are expanding, not contracting. We plan to dose our first subjects in the next weeks and expect to report phase I interim results later this year," said Dr. J. Joseph Kim, Inovio's president and CEO.

"It is an honor for our company to help usher this Zika vaccine through the clinical and regulatory process. We look forward to conducting this trial with the goal of achieving products to combat this dreaded virus," agreed Young K. Park, GeneOne's president and CEO.

The two companies are developing the Zika vaccine, GLS-5700, with academic collaborators from the United States and Canada with whom they previously collaborated to advance Inovio's Ebola and MERS vaccines into clinical development.

Currently there is no vaccine or therapy for the Zika virus.

Download Center

  • Hand Safety Program

    Hand injuries are the #1 preventable industrial accident worldwide. In REThinking Hand Safety, the most comprehensive book on hand safety, you'll learn how top companies have reduced hand injuries by up to 90% and what the most successful hand safety programs have in common. Get your free copy today!

  • Free 1-on-1 Consultations

    Is your company ready to reduce hand injuries? Schedule a free meeting with a Superior Glove hand safety expert and learn how to reduce hand injuries, lower PPE costs, and increase worker productivity. Our 1-on-1 consultations offer personalized advice and recommendations for your specific needs and concerns.

  • Glove 101 Guide

    Choosing the right safety gloves for your workers can be a daunting task. That’s where some basic knowledge of gloves can really come in handy! In this comprehensive guide you’ll find key information you need to know about safety gloves from types of gloves and materials to additives, treatments, safety standards, and more.

  • Sample Program

    Find the right safety gloves for your team and try before you buy—in just 3 easy steps! Simply add the products you want to try to your sample box, complete the sample request form, and wait for your samples to arrive at no cost to you.

  • Water Protection Product Guide

    Find the right safety gloves for your workers that are designed to protect in wet environments. From light and flexible to heavy duty, find the best water-resistant gloves with mechanical protection to safeguard workers.

  • Superior Glove

OH&S Digital Edition

  • OHS Magazine Digital Edition - November December 2022

    November December 2022

    Featuring:

    • IH: GAS DETECTION
      The Evolution of Gas Detection
    • OSHA TOP 10
      OSHA's Top 10 Most Frequently Cited Standards for FY 2022
    • FALL PROTECTION
      Enhance Your Fall Protection Program with Technology
    • 90TH ANNIVERSARY
      The Future: How Safety WIll Continue to Evolve
    View This Issue